Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Nanyang Biologics to list via $1.5bn SPAC — What it means for The9 investors and biotech markets
The9-backed Nanyang Biologics plans a $1.5B SPAC listing on Nasdaq. Find out what this means for AI drug discovery, The9’s stock, and investors.
ExQor Technologies moves closer to clinical trials with brain regenerative medicine for Alzheimer’s disease
ExQor Technologies advances toward clinical trials with a brain regenerative platform that could reverse Alzheimer’s damage and transform dementia care.
Zydus Lifesciences stock edges higher as Sentynl faces FDA CRL for CUTX-101
Zydus Lifesciences’ U.S. unit Sentynl received an FDA Complete Response Letter for CUTX-101. Find out why investors remain optimistic despite regulatory delays.
Pfizer just flipped the script on drug prices—now Eli Lilly and Amgen are ripping. Is this the start of a new pharma bull run?
Pfizer’s U.S. drug-pricing pact triggers a pharma relief rally. See what it means for Eli Lilly, Amgen, and investors today—read the data-driven outlook.
Are investors underestimating Enanta after Jefferies’ upgrade on RSV drug zelicapavir?
Jefferies upgrades Enanta Pharmaceuticals (NASDAQ: ENTA) to Buy on zelicapavir RSV trial promise; stock outlook, financing, and market sentiment inside.
Binaytara Foundation’s Lagos cancer pact with Federal Medical Center Ebute Metta promises safer chemo, workforce training, and a robust oncology registry
Find out how Binaytara Foundation and Federal Medical Center Ebute Metta plan to transform cancer care in Nigeria with safer chemo, training, and data.
Why Leo Pharma’s completed Spevigo deal with Boehringer could reshape rare skin disease care
Leo Pharma completes its acquisition of Spevigo® from Boehringer Ingelheim. Learn how this rare disease drug strengthens its dermatology growth strategy.
Biocon wins U.S. launch date for Prolia and Xgeva biosimilars—Can Amgen keep investors calm?
Amgen settles with Biocon for denosumab biosimilars, paving way for Bosaya and Aukelso U.S. launch from Oct 2025. What this means for biotech and investors.
Why Alpha Cognition raised $35m now — And what it means for Alzheimer’s drugs
Alpha Cognition (Nasdaq: ACOG) raises $35M in an oversubscribed public offering to drive Alzheimer’s therapy ZUNVEYL—see how investors are reacting.
Enanta (NASDAQ: ENTA) prices $65m offering at $10 per share — Is this a lifeline or a warning sign?
Enanta Pharmaceuticals (NASDAQ: ENTA) raises $65M in stock offering at $10 per share. Explore dilution risks, investor sentiment, and future outlook.